Spyre Therapeutics, Inc.
SYRE • NASDAQ
Spyre Therapeutics, Inc. is a biotechnology company in the healthcare sector trading on NASDAQ, led by CEO Cameron Turtle, with a market cap of $3.7B.
CEOCameron Turtle
Next Earnings
Upcoming earnings announcement for Spyre Therapeutics, Inc.
Date
Thursday, May 7, 2026 (in a month)
Timing
After Market Close (4:00 PM New York)
Fiscal Period
Q1 2026
EPS Estimate
-$0.66
Earnings History
Past 12 earnings reports for Spyre Therapeutics, Inc.
| Date | Period | EPS | EPS Surprise | Revenue | Rev. Surprise | Filing |
|---|---|---|---|---|---|---|
| Feb 19, 2026 | Q4 2025 | -$0.70Est: -$0.74 | +5.4% | -Est: $111.1K | -100.0% |  10-K |
| Nov 4, 2025 | Q3 2025 | -$0.15Est: -$0.72 | +79.2% | - | — | 10-Q |
| Aug 5, 2025 | Q2 2025 | -$0.49Est: -$0.72 | +31.9% | - | — | 10-Q |
| May 8, 2025 | Q1 2025 | -$0.62Est: -$0.82 | +24.4% | -Est: $4.0M | -100.0% | 10-Q |
| Feb 27, 2025 | Q4 2024 | -$0.81Est: -$0.97 | +16.5% | -Est: $2.3M | -100.0% | 10-K |
| Nov 7, 2024 | Q3 2024 | -$1.36Est: -$0.83 | -63.9% | - | — | 10-Q/A |
| Aug 7, 2024 | Q2 2024 | -$0.86Est: -$0.95 | +9.5% | - | — | — |
| May 9, 2024 | Q1 2024 | -$1.20Est: -$1.17 | -2.6% | - | — | — |
| Feb 29, 2024 | Q4 2023 | -$4.05Est: -$0.78 | -419.2% | -Est: $220.0K | -100.0% | — |
| Nov 9, 2023 | Q3 2023 | -$9.34Est: -$0.84 | -1011.9% | - | — | — |
| Aug 11, 2023 | Q2 2023 | -$41.50Est: -$3.75 | -1006.7% | $688.0KEst: $200.0K | +244.0% | — |
| May 11, 2023 | Q1 2023 | -$5.00Est: -$4.50 | -11.1% | $198.0KEst: $120.0K | +65.0% | — |